Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 vaccines in immunocompromised patients (COVERALL)
NCT04805125Phase 3Completed
- Sponsor
- University Hospital Basel
- Start
- Apr 2021
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elasomeran and tozinameran in coronavirus disease 2019 (COVID-19), sponsored by University Hospital Basel. Started Apr 2021; status: completed.
02
Drugs
elasomerantozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04805125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04805125.